



Cumulative Index 2003

Volume 23

March	PRION DISEASES, pages 1-256
June	PRENATAL TESTING, pages 257-568
September	GYNECOLOGIC CYTOPATHOLOGY, pages 569-780
December	MOLECULAR METHODS IN DIAGNOSTIC MICROBIOLOGY, pages 781-958

Note: Page numbers of article titles are in **boldface** type.

A

Abacavir, for HIV infection, resistance to, 919

Abortion, spontaneous, human chorionic gonadotropin measurement in, 262

Abruptio placenta, preterm delivery in, 348, 351-352

Accuprobe, for nontuberculous mycobacteria identification, 813

Acetylcholinesterase, in amniocentesis, 461

Achondroplasia, prenatal diagnosis of, 487-488

Acid elution test, for hemoglobin F, 332-333

Acid-fast bacillus smear microscopy for *Mycobacterium tuberculosis*, 801-802
for nontuberculous mycobacteria, 812

Acridine derivatives, for prion diseases, 191, 199

Acyclovir, for herpes simplex virus infections, 853

Adenocarcinoma, gynecologic, versus adenocarcinoma in situ, 636-639

Adenocarcinoma in situ, gynecologic, 636-639
diagnosis of, interobserver variability and reproducibility in, 643-644
versus benign mimics, 640-642

Adhesion molecules, in ovarian cancer effusions, 736, 738

Age

gestational, determination of, in prenatal testing, 546-547

maternal, Down syndrome screening and, 396-398, 547-548

ahpC gene mutations, in *Mycobacterium tuberculosis*, resistance in, 808, 824-825

Alloimmunization, Rh, hemolytic disease of the fetus and newborn in, 319-321, 327-332

Alpha-fetoprotein. *See also* Prenatal testing, epidemiologic monitoring of; Triple test.
biology of, 386
in Down syndrome screening, 397-398
in neural tube defect screening
historical aspects of, 386-387
in maternal diabetes mellitus, 388-389
in twin pregnancy, 389
laboratory aspects of, 392-393
MoM calculations in, 387-389
performance evaluation in, 389
protocol for, 390-392
versus normal levels, 386
in preeclampsia prediction, 424-426
in trisomy 18 screening, 404

Alternaria, molecular methods for, gene amplification methods, 784

Alveolar cells, type II (LBs), count of, in fetal lung maturity, 371-372

Alzheimer's disease
versus Creutzfeldt-Jakob disease, 13

Alzheimer's disease (*continued*)
versus Gerstmann-Sträussler-Scheinker syndrome, 66, 73

Amniocentesis
for bilirubin measurement, 329-331
for cytogenetic studies, 458-463
after chorionic villi sampling, 465
early, 460-461
indications for, 458
laboratory methodology for, 461-463
risks of, 459-460
techniques for, 458-459

for Down syndrome, 395-398, 402

for fetal lung maturity testing. *See* Fetal lung maturity.

for infection detection
cytomegalovirus, 311
herpes simplex virus, 309
parvovirus B19, 302, 334-335
toxoplasmosis, 299
varicella, 306

for neural tube defects, 390

Amphotericin B, for prion diseases, 192-194

Amplicor MTB assay, for *Mycobacterium tuberculosis* detection, 803

Amplification refractory mutation detection system, for cystic fibrosis screening, 518-522

Amplified fragment length polymorphism analysis, for hospital and environmental pathogens, 892

Amprenavir, for HIV infection, resistance to, 920

Amyloidosis
hereditary, 65-85
animal studies of, 82
in cerebral amyloid angiopathy, 69, 81
in Gerstmann-Sträussler-Scheinker syndrome, 66-81
amyloid characterization in, 68-69
prion protein characterization in, 66-68
parenchymal, 66
with variable phenotypes, 81-82
in scrapie, 26-27, 143
treatment of, iododoxorubicin for, 195-196

Anaplasmosis, 868, 875-877

Ancillary testing in Bethesda System 2001 recommendations, 597-598

Anemia
Diamond-Blackfan, prenatal diagnosis of, 335
fetal, diagnosis of, 319-321
in hemolytic disease of the fetus and newborn, 319-321, 327-332

Anencephaly. *See* Neural tube defects, open.

Angelman syndrome, prenatal diagnosis of, 473-474, 490-493

Angiogenic molecules, in ovarian cancer effusions, 740-741

Angiopathy, cerebral amyloid, 69, 81

Annexins, as phospholipid-binding cofactors, 272, 282

Anogenital cancer, human papillomavirus in, molecular techniques for, 909-911

Anthracyclines, for prion diseases, 190, 195-196

Antibody(ies)
cardiolipin, in antiphospholipid syndrome, 271-274
heterophilic, human chorionic gonadotropin test interference by, 261-262
phospholipid. *See* Antiphospholipid syndrome.
phospholipid-binding proteins, in antiphospholipid syndrome, 271-274
prion, for disease treatment, 199-200

Anticardiolipin antibodies, in antiphospholipid syndrome, tests for, 269-270

Antiphospholipid antibodies, in preeclampsia prediction, 427-428

Antiphospholipid syndrome, 265-293
antibody cross-reactions in, 270-271
autoimmune diseases with, 267
clinical manifestations of, 266-269
contentious issues in, 266
definition of, 265-266
laboratory tests for, 269-270
phospholipid-binding protein antibodies in, 271-274
pregnancy and, 274-283
antibody specificities in, 275-276
placental pathology in, 276-283
treatment of, 283-284
trophoblast as target in, 277-283

Antiretroviral agents, for HIV infection, resistance to, **915-928**
 evolution of, 915-916
 future directions of, 924, 926
 genotypic assays for, 917-921
 minority HIV populations and, 918
 phenotypic assays for, 921-922
 targets for, 916
 therapy selection and, 922-925
 transmission of, 916

Antivirogram assay, for antiretroviral agent resistance, 922

Arias-Stella reaction, in atypical endocervical cells, 634, 660

Arthritis, in Lyme disease, diagnosis of, molecular tools for, 872

Ascites, in ovarian cancer. *See* Ovarian cancer, effusions in.

ASCUS/LSIL Triage Study, **570-583**
 age factors in, 579-580
 biopsy management in, 574-576, 580-582
 colposcopy management in, 574-576, 580-582
 diagnostic reproducibility in, 576-579
 efficacy of, 574-576
 immature metaplastic cells importance in, 579
 longitudinal data of, 580-582
 objectives of, 571-572
 quality control aspects of, 572-573
 rationale for, 571
 results of, 620-621, 670-671
 squamous intraepithelial lesion grade and, 573-574
 test parameters in, 579-580

Aspergillus, molecular methods for epidemiologic typing, 792
 gene amplification, 784-786
 targets of, 782

Aspiration pneumonia, in chronic wasting disease, 149

Aspirin
 for antiphospholipid syndrome, 283-284
 for preeclampsia prevention, 419-420

Ataxia, cerebellar, in variant Creutzfeldt-Jakob disease, 88

Atrophy, cervicovaginal, **657-677**
 age factors in, 664
 atypia associated with, 617, 664-672
 causes of, 657-658
 drug effects on, 663-664
 hormone effects on, 658-664
 in medroxyprogesterone therapy, 661, 671-672
 in menopause, 663, 665-669
 in postpartum state, 661, 671
 in vitamin deficiency, 664
 liquid-based specimens and, 672
 maturation index and, 658-662
 moisturizer effects on, 664
 radiation-induced, 664
 treatment of, 669-671
 versus normal cytology, 658

Atypical glandular cells, **631-655**
 adenocarcinoma in situ, 636-644
 atypical endocervical cells
 favor neoplastic, 634-635
 not otherwise specified, 633-634
 atypical endometrial cells, 635-636
 benign mimics of adenocarcinoma in situ, 640-642
 Bethesda System 2001 reporting system for, 631-633
 classification of, 631-633
 diagnosis of, interobserver variability and reproducibility in, 643-644
 liquid-based preparations and, 647-648
 management algorithm for, 648-650
 prevalence of, 644-646
 significance of, 646-647

Atypical squamous cells, **605-630**
 atrophy with, 617
 atypical repair, 616-617
 Bethesda System 2001 classification of, 594-596
 cervicovaginal atrophic patterns and, 664-672
 in medroxyprogesterone therapy, 671-672
 in menopause, 665-671
 in postpartum state, 671
 human papillomavirus testing in, 619-621, 623
 in menopause, 618-619, 622, 665-671
 management of, 621-623
 of unknown significance. *See also* ASCUS/LSIL Triage Study.
 atrophy and, 617, 667-670
 definition of, 665
 differential diagnosis of, 609
 human papillomavirus testing of, 619-620, 707, 711-712
 in immunosuppression, 622
 in menopause, 618-619, 622
 in pregnancy, 622
 management of, 621-623
 morphology of, 608-611
 prevalence of, 644-646
 quality assurance considerations in, 623-626

Atypical squamous cells (*continued*)
 rescreening for, in quality control, 697-702
 subclassification of, 605-608
 terminology of, 605-608
 parakeratosis, 617
 quality assurance in, 623-626
 reporting of, 623
 rule out high-grade squamous intraepithelial lesions (ASC-H)
 management of, 622-623
 morphology of, 611-616
 subclassification of, 579
 terminology of, 605-608

Autoimmune disease, reproductive failure in. *See* Antiphospholipid syndrome.

Automation, of gynecologic cytology. **753-772**
 Bethesda System 2001
 recommendations on, 598-599
 for quality control, 702-703
 historical development of, 754-756, 759-760
 liquid-based preparation methods for, 756-759
 need for, 753-754
 screening, 759-768
 AutoPap/Focal Point System, 697-698, 755, 760, 762-765
 Cytoc Computerized Scanning Device, 767-768
 Focal Point GS System, 765-767
 historical development of, 759-760
 location guided, 756, 760
 PapNet System, 755, 761-762
 SurePath System, 757-759
 ThinPrep Pap Test, 757-758
 technology selection for, 689-690

Autonomic dysfunction, in familial fatal insomnia, 55-56

AutoPap/Focal Point System, 697-698, 755, 760, 762-765

Autosomal-dominant disorders, prenatal diagnosis of, 487-488

Autosomal-recessive disorders, prenatal diagnosis of, 487

B

B72.3 antibody, in ovarian cancer effusions, 730

BACTEC systems
 for *Mycobacterium tuberculosis* detection, 802

for *Mycobacterium tuberculosis* susceptibility, 804-805

Bacterial vaginosis, cytology of, Bethesda System 2001 classification of, 592

BAL protein, E6 protein abrogation of, 710

BDProbeTec ET, for *Mycobacterium tuberculosis* detection, 803

Behavioral changes, in chronic wasting disease, 148-149

Ber-EP4 antibody, in ovarian cancer effusions, 730, 732-733

Bethesda System 2001, **585-603**
 ancillary testing in, 597-598
 atypical squamous cells, 594-595
 benign cellular changes, 590, 592
 benign endometrial cells, 596-597
 computer-assisted diagnosis in, 598-599
 general categorization in, 586
 glandular lesion including atypical glandular cells, 595-596
 history of, 585, 587
 infections, 590, 592
 nomenclature of, 586-587
 recommendations for, 587, 591-601
 specimen adequacy in, 586, 588-591
 squamous intraepithelial lesions, 587, 593-594
 workshop for, 587-588

BG8 antibody, in ovarian cancer effusions, 730-731

Bilirubin, in amniotic fluid, 329-331

BioNumerics program, for outbreak analysis, 891

Biopsy
 brain, in herpes simplex virus encephalitis, 855-856
 in cervical cytology
 as gold standard, 694
 in ASCUS/LSIL Triage Study, 574-576, 580-582
 lymph node, in scrapie, 145
 skin, fetal, for cytogenetic studies, 471
 tonsil
 in prion diseases, 118-119
 in variant Creutzfeldt-Jakob disease, 89

Bladder, outlet obstruction of, in fetus, 468-469

Blastomyces dermatitidis, molecular methods for, nucleic acid probes, 782-783

BLK protein, E7 protein inactivation of, 710

Blood, fetal
sampling of, for cytogenetic studies, 469-471
typing of, 329

Blood culture, for cytogenetic studies, 470-471

Blood transfusions. *See* Transfusions.

Blood urea nitrogen, in preeclampsia, 421

Bone marrow, failure of, in fetus, 334-335

Borreliosis. *See* Lyme disease.

Bovine spongiform encephalopathy, 140
neuroanatomic features of, 8-10
transmission of, to humans, 8-10
variant Creutzfeldt-Jakob disease and, 87, 104-106

Brain
atrophy of
in familial fatal insomnia, 56-57
in Gerstmann-Sträussler-
Scheinker syndrome, 73-75
biopsy of, in herpes simplex virus
encephalitis, 855-856
prion diseases of. *See* Prion diseases;
specific diseases.

Brain-derived neurotrophic factor, in
ovarian cancer effusions, 739

Brain scan, in variant Creutzfeldt-Jakob
disease, 89

Branch migration inhibition method, in
Mycobacterium tuberculosis resistance
detection, 809-810

Branched polyamines, for prion diseases, 191, 198-199

Burkitt's lymphoma, Epstein-Barr virus
infections associated with, molecular
techniques for, 906-907

C

Cadherins, in ovarian cancer effusions, 730,
732-733

Calcium
in urine, in preeclampsia prediction,
429-430
supplementation with, for
preeclampsia prevention, 420

Calretinin, in ovarian cancer effusions,
732

Campylobacter jejuni, molecular
epidemiology of, 888

Cancer
cervical
cytology of. *See* Gynecologic
cytology.
human papillomavirus in.
See Human papillomavirus.
infections associated with, molecular
techniques for, 903-913
Epstein-Barr virus, 905-907
historical review of, 903-904
human papillomavirus, 909-911
Kaposi's sarcoma-associated
herpesvirus-8, 907-909
types of, 904-905
ovarian. *See* Ovarian cancer.

Candida, molecular methods for
epidemiologic typing, 790-794
gene amplification, 783-785, 787, 789
targets of, 782

Capillary immunoelectrophoresis, in prion
diseases, 120

Carcinoembryonic antigen, in ovarian
cancer effusions, 730

Carcinoma, ovarian. *See* Ovarian cancer.

Cardiolipin, antibodies to, in
antiphospholipid syndrome, 269-270

Carrageenans, for prion diseases, 188

Castleman's disease, multicentric,
herpesvirus-8 infections associated
with, molecular techniques for, 907-909

Catenins, in ovarian cancer effusions, 736

Cattle
prion protein of, structure of, 214
spongiform encephalopathy of. *See*
Bovine spongiform
encephalopathy.

Caveolin-1, in ovarian cancer effusions,
738-739

CD14, in ovarian cancer effusions, 732-733

CD44, in ovarian cancer effusions, 730-731

CD45, in ovarian cancer effusions, 732-733

Cell adhesion molecules, in preeclampsia
prediction, 430-431

Cell culture
of cytomegalovirus, 311
of enteroviruses, 845, 848-849
of herpes simplex virus, 308-309,
853-854

Cell culture (continued)
prion replication in, 230-232

Central nervous system, viral infections of, molecular diagnosis of, 843-865
enterovirus, 844-851
herpes simplex virus, 851-858
JC virus, 858-859

Centrifugation, for pulmonary surfactant analysis, 367-368

Centromeric probes, for FISH, 475

Centrosomes, abnormalities of, as human papillomavirus surrogate markers, 720

Cerebellar ataxia, in variant Creutzfeldt-Jakob disease, 88

Cerebral amyloid angiopathy, 69, 81

Cerebrospinal fluid analysis
in enteroviral infections, 870-875
in herpes simplex virus encephalitis, 856-858
in Lyme disease, 872-873
in variant Creutzfeldt-Jakob disease, 89

Cervical cancer
cytology of. *See* Gynecologic cytology.
human papillomavirus and. *See* Human papillomavirus.

Cervicovaginal cytology. *See* Gynecologic cytology.

CFTR gene and product
function of, 509
mutations of, 506-507, 510-512, 517
polymorphisms of, 511-512
preimplantation screening for, 517
structure of, 509

Chaperone molecules, in prion protein conversion, 230

Chef-DR III horizontal system, for nontuberculous mycobacteria typing, 815

Chemokines, in ovarian cancer effusions, 740-741

Chickenpox, prenatal diagnosis of, 296, 305-307

Chlamydia infections, gynecologic, cytology of, Bethesda System 2001 classification of, 592

Chlorpromazine, for prion diseases, 34, 199

Cholesterol inhibitors, for prion diseases, 201

Chorioamnionitis, from amniocentesis, 459-460

Chorionic villi sampling
for cytogenetic studies, 463-467
indications for, 463-464
laboratory methodology for, 466-467
risks of, 465-466
techniques of, 464-465
for Down syndrome, 395-396

Chromatography
in hemoglobin analysis, 323-324
in mycolic acid analysis, for nontuberculous mycobacteria detection, 813
thin-layer, in pulmonary surfactant analysis, 368

Chromosome(s)
abnormalities of, cytogenetic studies of. *See* Cytogenetics.
analysis of, in amniotic fluid, 462-463
marker, for FISH, 458-476

Chronic wasting disease, of deer and elk, 140, 148-154
clinical features of, 148-149
diagnosis of, 151-153
epidemiology of, 148
host range of, 153-154
pathogenesis of, 153
pathology of, 149-150
transmission of, 154

Cladosporium, molecular methods for, gene amplification, 784

Cleavase VI invader assay, in *Mycobacterium tuberculosis* resistance detection, 830

Coagulation tests
in antiphospholipid syndrome, 269
in preeclampsia, 422

Coccidioides immitis, molecular methods for, nucleic acid probes, 782-783

Collagen, in ovarian cancer effusions, 736

Collagenases, in ovarian cancer effusions, 735-736

Colominic acid, sulfated, for prion diseases, 201

Colony-stimulating factor-1, in ovarian cancer effusions, 741

Colorimetric assay, for *Mycobacterium tuberculosis* susceptibility, 805

Colposcopy
 in ASCUS/LSIL Triage Study, 574-576, 580-582
 in atypical glandular cell management, 650

Computed tomography, in variant Creutzfeldt-Jakob disease, 89

Conformation-dependent immunoassay, for protease-resistant prion proteins, 122

Congo red, for prion diseases, 190, 194-195

Cordocentesis, for cytogenetic studies, 469-471

Corticotropin-releasing hormone
 excess of, preterm delivery in, 345-347, 349-350
 in preeclampsia prediction, 426

Cortisol, excess of, preterm delivery in, 346-347

Coxsackievirus infections, of central nervous system, 844-851
 classification of, 844
 epidemiology of, 844-845
 molecular aspects of, 845-846
 nucleic acid sequence-based amplification detection of, 850-851
 reverse transcriptase-polymerase chain reaction detection of, 846-850
 traditional detection methods for, 845

Creatinine clearance, in preeclampsia, 421

Creutzfeldt-Jakob disease
 hereditary, 43-54
 deletion mutations in, 47, 54
 diagnosis of
PRNP gene mutations in, 48-49
 protein 14-3-3 type in, 111-112
 D178N-129V haplotype, 46, 49-50
 E200K-129M haplotype, 45-46, 48
 E200K-129V haplotype, 46, 48-49
 ethnic factors in, 45, 49-51
 INS-129M haplotypes, 47
 insertion mutations in, 52-54
 M232R-129M haplotype, 47, 51-52
 murine model of, 175-186
 mutations in, 27-29, 220
 neuroanatomic features of, 8
 prion proteins in, 27-29, 44, 48-54

T183A-129M haplotype, 46, 50-51
 V180I-129M haplotype, 46, 51-52
 V210I-129M haplotype, 46, 50

iatrogenic, 8, 129-130
 neuropathology of, 8, 25
 prion proteins of
 hereditary, 48-54
 polymorphisms of, 237
 sporadic, 30-31
 structures of, 102-103
 variant, 89, 99-104

sporadic, 46
 diagnosis of
 capillary immunoelectrophoresis in, 120
 clinical, 110-114
 conformation-dependent immunoassay in, 122
 infectivity assays in, 119
 neuropathologic methods for, 116-119
 scanning for intensely fluorescent targets in, 110
 urine tests in, 121-122
 versus hereditary, 115
 epidemiology of, 13
 from blood transfusions, 133-134
 iatrogenic, 129-130, 133-134
 neuropathology of, 8, 30-31
 prion proteins of, 30-31
 versus Alzheimer's disease, 13
 versus hereditary Creutzfeldt-Jakob disease, 45, 52-54

surveillance for, 132
 uncommon forms of, 118
 variant, 87-108
 bovine spongiform encephalopathy and, 87, 104-106
 clinical features of, 87-89
 diagnosis of
 clinical, 110-112
 conformation-dependent immunoassay in, 122
 genetic, 115
 infectivity assays in, 120
 neuropathologic methods for, 116-119
 urine tests in, 121-122
 epidemiology of, 32-33, 89-97
 genetic factors in, 103
 history of, 32-33
 laboratory testing in, 89
 neuropathology of, 8-10, 97-100
 peripheral pathology in, 100-104
 prion proteins of, 89, 99-104
 transmission of, 130-131, 134-135

Creutzfeldt-Jakob disease (*continued*)
uncertainties in, 105-106
versus Creutzfeldt-Jakob disease, 133-134
versus Alzheimer's disease, 13
versus Gerstmann-Sträussler-Scheinker syndrome, 70
versus variant Creutzfeldt-Jakob disease, 133-134

Cri-du-chat syndrome, prenatal diagnosis of, 474

Cryptococcus neoformans, molecular methods for, gene amplification, 787

Culture
blood, for cytogenetic studies, 470-471
of enteroviruses, 845, 848-849
of herpes simplex virus, 853-854
of nontuberculous mycobacteria, 812
tissue
of amniotic fluid, 461-462
of chorionic villi, 466-467

Cyanophilic bodies, in cervicovaginal atrophy, 662

Cyclin E, as human papillomavirus surrogate marker, 716-718

Cystic fibrosis, 503-530
birth prevalence in, 508-509
clinical features of, 505-506
epidemiology of, 503
ethnic variability in, 503, 508-509
gene of, 509-512
mutations in, 506-507, 510-512, 517
genotype/phenotype correlations in, 511-512
inheritance of, 506-507
prenatal screening for
confirmatory testing in, 523
ethical issues in, 516-517
expected performance in, 514-516
guidelines for, 524-525
importance of, 503-504
legal issues in, 516-518
methods for, 518-522
models for, 512-513
molecular genetic methods in, 487
oversight requirements in, 524-525
performance evaluation of, 522-523
pilot trials of, 513-514
quality assurance in, 525-526
social implications of, 516-518
prognosis for, 507
treatment of, 507

Cystic hygroma fluid, cytogenetic studies of, 467

Cytogenetics, in prenatal diagnosis, 457-480
amniotic fluid for, 458-463, 465
chorionic villi sampling for, 463-467
cystic hygroma fluid for, 467
fetal blood for, 469-471
fetal skin biopsy for, 471
fetal urine for, 468-469
molecular, 473-477
parental blood samples for, 472-473
results of, 471-473

Cytokines
in ovarian cancer effusions, 740-741
in preeclampsia prediction, 428-429
preterm delivery and, 351

Cytomegalovirus infections, prenatal diagnosis of, 296, 309-311

Cytotrophoblast, as antiphospholipid antibody target, 278, 281-283

Cytoc Computerized Scanning Device, for cervical cytology, 767-768

D

Dapsone, for prion diseases, 202

Decidual hemorrhage, preterm delivery in, 348, 351-352

Deer, chronic wasting disease of. *See* Chronic wasting disease.

Dehydroepiandrosterone sulfate, excess of, preterm delivery in, 347

Delavirdine, for HIV infection, resistance to, 919

Denaturing gradient gel electrophoresis, in *Mycobacterium tuberculosis* resistance detection, 809

Dermatophytes, molecular methods for
epidemiologic typing, 791
gene amplification, 785-786
targets of, 782

Desmin, in ovarian cancer effusions, 732

Diabetes mellitus
gestational. *See* Gestational diabetes.
neural tube defect screening in, MoM adjustments in, 388-389

Diamond-Blackfan anemia, prenatal diagnosis of, 335

Didanosine, for HIV infection, resistance to, 919

Dideoxynucleotide cycle sequencing
genotype assays, for antiretroviral agent resistance, 917-918

Diet, for gestational diabetes, 445-446

Differential agglutination test, in toxoplasmosis, 298

DiGeorge syndrome, prenatal diagnosis of, 474

Dissociation-enhanced lanthanide fluoroimmunoassay, in prion diseases, 120

DNA analysis
for ovarian cancer effusions, 733-734
for prenatal diagnosis. *See* Molecular methods, for genetic testing, in prenatal diagnosis.
microarray. *See* Microarray technology.
randomly amplified polymorphic (RAPD)
for fungal pathogens, 792
for hospital and environmental pathogens, 891-892

DNA probes
for herpesvirus-8, 908-909
for hospital and environmental pathogens, 886-887
with restriction fragment length polymorphism analysis, for fungal pathogens, 791

DNA sequencing
in *Mycobacterium tuberculosis* resistance detection, 807-808, 827
in prenatal diagnosis, of genetic disorders, 485

Doppel protein
function of, 219-221
structure of, 209-211, 215-217, 219-220

Doppler ultrasound, in preeclampsia prediction, 423-424

Dot-blot hybridization, in *Mycobacterium tuberculosis* resistance detection, 831

Down syndrome, prenatal screening for, 395-411
alpha-fetoprotein, 397-398
clinical trials of, 403
concepts of, 395-396
epidemiologic monitoring of, 531-551
first-trimester, 398-403
goals of, 395-396

in early pregnancy, 398-399
laboratory considerations in, 405-408
maternal age and, 396-398
MoM calculation in. *See* Multiple of the median (MoM).
new methods for, 398-403
other abnormalities identified in, 403-405
preeclampsia prediction from, 424-426
reasons for, 396
reference data for, 405-407
risk interpretation in, 407-408
second-trimester, 398, 402-403
triple test in, 398
ultrasonography in, 399-401

Doxycycline, for prion diseases, 196-197

DS500, for prion diseases, 188, 192

Duchenne muscular dystrophy, prenatal diagnosis of, 488-490

Dura mater grafts, prion disease transmission in, 130

E

E-cadherins, in ovarian cancer effusions, 730, 736

E6 protein, human papillomavirus, 710-711

E7 protein, human papillomavirus, 710-711

E-selectin, in preeclampsia prediction, 430

Eclampsia, definition of, 416

Economic issues, in gynecologic cytology, technology selection and, 681-682, 687-691

Ectopic pregnancy, testing of, 260-261

Edwards syndrome (trisomy 18), prenatal screening for, 404

Efavirenz, for HIV infection, resistance to, 919

Effusions, in ovarian cancer. *See under* Ovarian cancer.

Ehrlichiosis
granulocytic ewingii, 877-878
human granulocytic (anaplasmosis), 868, 875-877
human monocytic, 874-875
organisms causing, 873-874

Electroencephalography
in Creutzfeldt-Jakob disease, 110-111
in familial fatal insomnia, 56
in variant Creutzfeldt-Jakob disease, 89

Electrophoresis
capillary, in prion diseases, 120
in *Mycobacterium tuberculosis*
resistance detection, 809,
827-830
of hemoglobin, in prenatal diagnosis,
322-323
pulsed-gel
in hospital infections, 887-891
in nontuberculous mycobacteria
typing, 815
in public health environment
infections, 887-891

Electrophoretic karyotyping, for fungal
pathogens, 789

Elk, chronic wasting disease of. *See* Chronic
wasting disease.

embB gene mutations, in *Mycobacterium*
tuberculosis, resistance in, 826

Encephalitis
enteroviral. *See* Enteroviral infections,
of central nervous system.
herpes simplex virus. *See* Herpes
simplex virus infections, of
central nervous system.

Encephalomyelitis, in Lyme disease,
diagnosis of, molecular tools for,
872-873

Encephalopathy(ies), transmissible
spongiform. *See also* Prion diseases.
bovine. *See* Bovine spongiform
encephalopathy.
mink, 139, 234-235

Endocervical adenocarcinoma in situ, in
Bethesda System 2001, 595-596

Endocervical cells, atypical
favor neoplastic, 634-635
not otherwise specified, 633-634

Endocervical component, in Bethesda
System 2001, 588-589

Endocervical hyperplasia, microglandular,
640-641

Endometrial cells
atypical, 635-636
benign, Bethesda System 2001
classification of, 596-597

Endothelial dysfunction, in preeclampsia
prediction, 426-427

Endothelins, in preeclampsia prediction,
426-427

Enhanced Amplified Mycobacterium
Tuberculosis Direct Test, 803

Entactin, in ovarian cancer effusions, 736

Enteric nervous system, scrapie entering,
147

Enterobacteriaceae, molecular
epidemiology of, 891-892

Enteroviral infections, of central nervous
system, 844-851
classification of, 844
epidemiology of, 844-845
molecular aspects of, 845-846
nucleic acid sequence-based
amplification detection of,
850-851
reverse transcriptase-polymerase chain
reaction detection of, 846-850
traditional detection methods for, 845

Enzyme immunoassay
in HIV infection, 303-304
in parvovirus infections, 301, 334

Enzyme-linked immunosorbent assay
in antiphospholipid syndrome,
269-270
in Down syndrome screening, 405
in toxoplasmosis, 298-299

Epidemiologic monitoring, of prenatal
screening. *See* Prenatal testing,
epidemiologic monitoring of.

Epidemiologic typing methods, for fungal
pathogens, 789-794
amplification techniques, 790-794
electrophoretic karyotyping, 789
restriction fragment length
polymorphism analysis,
789-790

Epidermolysis bullosa, fetal skin biopsy for,
471

Epsilometer test, for *Mycobacterium*
tuberculosis susceptibility, 805-806

Epstein-Barr virus infections, cancer-
associated, molecular techniques for,
905-907

Erythema infectiosum (parvovirus B19
infection), prenatal diagnosis of, 296,
299-302, 334-335

Erythema migrans, in Lyme disease,
diagnosis of, molecular tools
for, 871

Erythroid differentiation-related factor in, in Creutzfeldt-Jakob disease, 114

Erythropoiesis, development of, 318-319

Escherichia coli, molecular epidemiology of, 887-888, 894-895

ESP Culture System II
for *Mycobacterium tuberculosis* detection, 802
for *Mycobacterium tuberculosis* susceptibility, 805

Estriol, unconjugated. *See also* Prenatal testing, epidemiologic monitoring of; Triple test.
assays for, 405
in Down syndrome screening, 398
in preeclampsia prediction, 424-426
in trisomy 18 screening, 404

Estrogens
cervicovaginal atrophy and, 658-664
excess of, preterm delivery and, 350

Ethambutol, resistance to, in *Mycobacterium tuberculosis*, 826

Ethic factors, in hereditary Creutzfeldt-Jakob disease, 45, 49-51

Ethical issues, in cystic fibrosis prenatal screening, 516-517

ETs-1 transcription factor, in ovarian cancer effusions, 743-745

Ewingii granulocytic ehrlichiosis, 877-878

Exophiala, molecular methods for, gene amplification, 784

Extracellular matrix metalloproteinase inducer, in ovarian cancer effusions, 738, 741

F

False-positive rate, in prenatal screening
definition of, 532
gestational dating and, 546

Familial Creutzfeldt-Jakob disease. *See* Creutzfeldt-Jakob disease, hereditary.

Familial fatal insomnia. *See* Fatal insomnia, familial.

Fas receptor and ligand, in preeclampsia prediction, 428-429

Fasting, glucose studies in, in gestational diabetes, 448-449

FASTPlaqueTB assay, 806

Fatal insomnia
familial, 47, 55-58
diagnosis of, *PRNP* gene mutations in, 48-49
murine model for, 175-186
mutations in, 27-29, 220
neuroanatomic features of, 8
prion proteins in, 30-31
sporadic, neuropathology of, 8, 30-31

Fetal lung maturity, pulmonary surfactant in, 361-383
composition of, 364-365
properties of, 366-367, 370-372
tests for, 362, 365-367
centrifugation in, 367-368
chromatographic separation in, 368
combinations of, 372
fluorescence polarization, 370-371
functional surfactant assay in, 371
historical aspects of, 361, 363-364
in oligohydramnios, 375-376
in polyhydramnios, 375-376
in premature rupture of membranes, 374-375
in twin gestation, 373-374
Lung Profile, 368-369
phospholipid extraction in, 368
physical property evaluation in, 370-372
racial differences in, 376
saturated phosphatidylcholine, 366-367, 369-370
type II storage form (LBs), 371-372
visualization in, 368

Fetomaternal hemorrhage, detection of, 332-334

Fetus
blood sampling from, for cytogenetic studies, 469-471
chromosomal studies of, 457-480
cystic fibrosis screening of, 503-530
DNA analysis of, in preeclampsia prediction, 431
hematologic disorders in, testing for, 317-343
hypothalamic-pituitary axis activation in, 345-347, 349-351
infections in, testing for. *See* Infections, prenatal diagnosis of, loss of
in amniocentesis, 459-460
in chorionic villi sampling, 465

Fetus (continued)
in fetal blood sampling, 470
in trisomy 18, 404
monitoring of, in preeclampsia, 418
skin biopsy of, for cytogenetic studies, 471
urine of, cytogenetic studies of, 468-469

Fibrinogen, in ovarian cancer effusions, 736

Fibrinolytic activity, in preeclampsia prediction, 429

Fibroblastic growth factor, basic, in ovarian cancer effusions, 740

Fibronectin
fetal
in preeclampsia prediction, 426-427
preterm delivery and, 352-354
in ovarian cancer effusions, 736

FISH. *See* Fluorescence in situ hybridization (FISH).

Florid plaques, in variant Creutzfeldt-Jakob disease, 97-100, 116

Flow cytometry
in hemoglobin F detection, 333-334
in ovarian cancer effusions, 732-733

Fluipirtine, for prion diseases, 201

Fluorescence in situ hybridization (FISH).
for prenatal diagnosis
guidelines for, 473
interphase, 477
marker chromosomes in, 476-477
of bladder outlet obstruction, 468-469
of cystic hygroma, 467
probes for, 474-475

Fluorescence polarization, for pulmonary surfactant evaluation, 370-371

Fluoroimmunoassay, dissociation-enhanced lanthanide, in prion diseases, 120

Focal Point GS System, for cervical cytology, 765-767

Folate deficiency, cervicovaginal epithelial effects of, 664

Fonsecaea, molecular methods for, gene amplification, 785

Formic acid, in immunohistochemistry, in scrapie, 144

Fragile X (FRAX A) syndrome, prenatal diagnosis of, 495-496

Functional surfactant assay, for fetal lung maturity, 371

Fungal pathogens, molecular methods for, 781-799
electrophoretic karyotyping, 790
epidemiologic typing, 789-794
gene amplification, 783-789
nonamplification, 790-791
nucleic acid probes, 782-783
nucleic acid sequence analysis, 792-794
polymerase chain reaction, 783-789
RAPD assay, 792
restriction fragment length polymorphism analysis, 791-792
targets of, 781-782

G

Gardnerella vaginalis infections, cytology of, Bethesda System 2001 classification of, 592

Gastroschisis, alpha-fetoprotein levels in, 389

Glutaminases, in ovarian cancer effusions, 735-736

GelCompar program, for outbreak analysis, 891

Gene amplification methods. *See also* Polymerase chain reaction.
for fungal pathogens, 783-789

GeneChip technology, in *Mycobacterium tuberculosis* resistance detection, 832-834

Genetic factors
in cystic fibrosis, 506-507
in scrapie, 19-20
in variant Creutzfeldt-Jakob disease, 105

Genetic screening
in preeclampsia prediction, 431-432
molecular techniques for. *See* Molecular methods, for genetic testing.

Genital tract infections, preterm delivery in, 347-348, 351

Genotype kit, for nontuberculous mycobacteria identification, 814

Genotypic resistance assays, for HIV resistance, 917-921

Gerstmann-Sträussler-Scheinker syndrome, 161-173

human
A117V-129V haplotype of, 73
diagnosis of, *PRNP* gene
mutations in, 48-49
D202N-129V haplotype of, 77,
80
F198S-129V haplotype of, 75-79
G131V-129M haplotype of, 73
H187R-129V haplotype of, 74
M232T-129M/V haplotype of,
80-81
mutations in, 48-49, 220-221
neuropathology of, 8, 25
P102L haplotype of, 162-163
P102L-129M haplotype of, 69-70
P102L-129M-219K haplotype of,
70
P102L-129V haplotype of, 70-71
P105L-129V haplotype of, 71-72
prion proteins of. *See* Prion
proteins (PrPs), in
Gerstmann-Sträussler-
Scheinker syndrome.
Q212P-129M haplotype of, 80
Q217R-129V haplotype of, 80
versus Alzheimer's disease, 66, 73

murine
model for, 175-186
mutations in, 29-30
prion proteins in, 8, 29-30
type P101L, 163-171
disease transmission in,
164-168
infectivity in, 167, 169-170
mutation introduction in,
163-164
prion protein role in,
170-171

Gestational age, determination of, in
prenatal testing, 546-547

Gestational diabetes, 443-456
consequences of, 444-445
definition of, 443
diagnostic criteria for, 443-445
diagnostic tests for, 450-452
epidemiology of, 443
postpartum testing and, 452-454
risk factors for, 446-447
screening tests for, 446-450
treatment of, 445-446

Gestational hypertension, 417

Glandular lesions, Bethesda System 2001
classification of, 595-596

Gliosis
in familial fatal insomnia, 56-57
in hereditary Creutzfeldt-Jakob
disease, 49

Glucose polymer challenge test, in
gestational diabetes, 448

Glucose testing, in gestational diabetes
fasting, 448-449
glucose polymer, 448
intravenous, 451
oral challenge, 447-448
oral tolerance, 450-451
postmeal, 448-449
postpartum, 451-454
random, 448-449

Glycated blood proteins, in gestational
diabetes, 449-450

Glycoform profiles, of scrapie prion, 146

β_2 -Glycoprotein I
antibodies to, pregnancy
complications and, 275-276
as phospholipid-binding cofactor,
272-274

Glycosaminoglycans, sulfate, for prion
diseases, 3, 6

Goats, scrapie of. *See* Scrapie.

Grand MoM. *See under* Multiple of the
median (MoM), in prenatal screening
for neural tube defects and Down
syndrome.

Growth hormone, prion disease
transmission in, 130

Gynecologic cytology
atypical glandular cells in, 631-655
atypical squamous cells in. *See*
Atypical squamous cells.
automation in. *See* Automation of
gynecologic cytology.
Bethesda System 2001 in, 585-603
in atrophy, 617, 657-677
in human papillomavirus testing. *See*
Human papillomavirus.
gynecologic cytology for.
in ovarian cancer, 727-752
in pregnancy, 622, 634, 646, 660-661
molecular markers in, 707-726
normal cellularity in, 658
quality control in. *See* Quality control,
in cervical cytology.
technology selection for, 679-692
clinical community involvement
in, 684-691
final evaluation in, 686-687
financial factors in, 681-682,
687-691
method descriptions in, 680-682
personal factors in, 687-691
reasons for, 689-691

Gynecologic cytology (continued)
results of, 691-692
within-laboratory evaluation of, 682-684

H

Heat shock protein polymorphisms, for nontuberculous mycobacteria identification, 813

HELLP syndrome, 417

Hematocrit, in preeclampsia, 421-422

Hematologic disorders, prenatal diagnosis of, 317-343
anemia, 319-321, 335
bone marrow failure/suppression, 334-335
fetomaternal hemorrhage, 332-334
hemoglobinopathies, 321-327
hydrops, 319-320
immune hemolytic disease, 327-332
normal hematopoiesis and, 318-319
thalassemias, 321-327

Hematopoiesis, development of, 318-319

Hemoglobin
defects of, 318-319
embryonic, 319
structure of, 318

Hemoglobin Barts, prenatal detection of, 324-326

Hemoglobin C, prenatal detection of, 321, 323

Hemoglobin D Punjab, prenatal detection of, 323

Hemoglobin E, prenatal detection of, 321, 323

Hemoglobin F
in adults, 323
Kleihauer test for, 332-333

Hemoglobin G Philadelphia, prenatal detection of, 323

Hemoglobin O Arab, prenatal detection of, 323

Hemoglobinopathies, prenatal diagnosis of, 321-327

Hemolytic disease of the fetus and newborn, diagnosis of, 319-321, 327-332

Hemorrhage
decidual, preterm delivery in, 348, 351-352
fetomaternal, detection of, 332-334

Heparin, for antiphospholipid syndrome, 283-284

Herpes simplex virus infections
of central nervous system, 851-858
clinical manifestations of, 852-853
epidemiology of, 852-853
neonatal, 852-855
polymerase chain reaction for, 854-858
traditional detection methods for, 853-854
virology of, 851-852
prenatal diagnosis of, 296, 307-309

Herpesvirus-8 infections, molecular techniques for, 907-909

Heteroduplex analysis in *Mycobacterium tuberculosis* resistance detection, 809-810, 829

Heterophilic antibodies, human chorionic gonadotropin test interference by, 261-262

Heteropolyanion 23, for prion diseases, 188

Heterotopic pregnancy, testing of, 262

Histologic examination, in prion diseases, 115-116

Histoplasma capsulatum, molecular methods for
epidemiologic typing, 792-793
gene amplification, 788
nucleic acid probes, 782-783

Hodgkin's disease, Epstein-Barr virus infections associated with, molecular techniques for, 906-907

Homocysteine, in preeclampsia prediction, 427-428

Hormones, cervicovaginal atrophy and, 658-664

Hospital environment, molecular epidemiology in, 885-901
multilocus sequence typing in, 892-893
pathogens involved in, 893-894
plasmid typing methods for, 886
polymerase chain reaction in, 891-892
pulsed-field gel electrophoresis in, 887-891
restriction enzymes and probe methods in, 886-887
single-locus sequence typing in, 892-893

hsp 65 PCR restriction analysis, for nontuberculous mycobacteria identification, 813

Human chorionic gonadotropin. *See also* Prenatal testing, epidemiologic monitoring of; Triple test. elevation of, preterm delivery in, 350-351 in Down syndrome screening, 398-399, 401 in early pregnancy viability testing, 257-264 chemistry of, 257-258 ectopic, 260-261 heterophilic antibody interference with, 261-262 heterotopic, 262 in spontaneous abortion, 262 test types for, 258-259 timing of, 259-260 versus progesterone, 262-263 in preeclampsia prediction, 424-426 in trisomy 18 screening, 404

Human granulocytic ehrlichiosis (anaplasmosis), 868, 875-877

Human immunodeficiency virus infection antiretroviral resistance in, 915-928 evolution of, 915-916 future directions of, 924, 926 genotypic assays for, 917-921 minority virus populations and, 918 phenotypic assays for, 921-922 targets for, 916 therapy selection and, 922-925 transmission of, 916 Kaposi's sarcoma in, herpesvirus-8 infections associated with, molecular techniques for, 907-909 prenatal diagnosis of, 296, 302-305

Human monocytic ehrlichiosis, 874-875

Human papillomavirus cancer-associated, molecular techniques for, 909-911 gynecologic cytology for atrophy and, 669-671 atypical squamous cells and, 609, 619-623 clinical trials of. *See* ASCUS/LSIL Triage Study. efficacy of, 712 guidelines for, 711-712 molecular markers for, 707-726 centrosomes, 720 cyclin E, 716-718 E6 protein, 710-711

E7 protein, 710-711 Hybrid Capture II Test System in, 712-713 in situ hybridization in, 714 Ki-67 protein, 719-720 microarray technology, 721-722 P16INK4a protein, 715-716 polymerase chain reaction in, 713-714 proliferating cell nuclear antigen, 720 surrogate, 714-722 telomerase, 718-719 pathogenesis and, 708-710 technology selection for, 685-687

Hybrid II Capture II Test system, for human papillomavirus, 712-713

Hydrops fetalis bone marrow suppression in, 335 diagnosis of, 319-321

Hyperchromasia, in atypical glandular cells, 633-635

Hyperchromatic crowded groups, in cervicovaginal atrophy, 666

Hyperglycemia, tests for. *See* Glucose testing.

Hypertension chronic, preeclampsia superimposed on, 416-417 gestational, 417 in preeclampsia, 414-417 in pregnancy, classification of, 415-417

Hyperuricemia, in preeclampsia, 421

Hypothalamic-pituitary-adrenal axis, activation of, preterm delivery in, 345-347, 349-351

I

Immune response, in preeclampsia, 419

Immunization, for prion diseases, 199-200

Immunoassays, in Down syndrome screening, 405

Immunoblot test in familial fatal insomnia, 57-58 in parvovirus infections, 301 in scrapie, 145-146

Immunocytochemistry in variant Creutzfeldt-Jakob disease, 99-100 of ovarian cancer effusions, 729-732

Immunoelectrophoresis, capillary, in prion diseases, 120

Immunofluorescence tests, in parvovirus infections, 301

Immunoglobulin G avidity test, in toxoplasmosis, 298

Immunohistochemistry
in chronic wasting disease, 152
in prion diseases, 115-116
in scrapie, 142-144

Immunometric assays, for alpha-fetoprotein, in neural tube defects, 392

Immunosorbent agglutination assay, in toxoplasmosis, 298

Immunosuppression, atypical squamous cells in, 622

Implantation, genetic testing before, 497-498

In situ hybridization, for human papillomavirus, 714

Indinavir, for HIV infection, resistance to, 919

Indirect fluorescent antibody test, in toxoplasmosis, 298

Infections
cancer-associated, molecular tests for, 903-913
gynecologic, cytology of, Bethesda System 2001 classification of, 590, 592
prenatal diagnosis of, 295-315
cytomegalovirus, 296, 309-311
herpes simplex virus, 296, 307-309
human immunodeficiency virus, 296, 302-305
parvovirus B19, 296, 299-302, 334-335
summary of, 296
toxoplasmosis, 296-299
varicella, 296, 305-307

Infectivity assays, in prion disease, 119-120

inhA gene mutations, in *Mycobacterium tuberculosis*, resistance in, 824-825

Inhibin A
in Down syndrome screening, 398
in preeclampsia prediction, 424-426

Initial-positive rate, in prenatal screening cutoff levels and, 545
definition of, 532

gestational dating and, 546-547
inappropriate, 544
initial applications of, 534-535
maternal age and, 547-548
monitoring of, 543-544

INNO-LiPA assay
for *Mycobacterium tuberculosis*
resistance detection, 808, 830-831
for nontuberculous mycobacteria
identification, 814

Insomnia, fatal. *See* Fatal insomnia.

Insulin
for gestational diabetes, 445-446
resistance to, in preeclampsia
prediction, 430

Insulin-like growth factor binding protein 1, in preeclampsia prediction, 431

Integrated Test, in Down syndrome, 402

Integrins, in ovarian cancer effusions, 736, 738

Intercellular adhesion molecule 1, in preeclampsia prediction, 430

Interleukin-1, preterm delivery and, 347

Interleukin-2, in ovarian cancer effusions, 740

Interleukin-6, preterm delivery and, 351

Interleukin-8, in ovarian cancer effusions, 740

Interleukin-21, in ovarian cancer effusions, 741

Invader assay, in *Mycobacterium tuberculosis* resistance detection, 830

Iododoxorubicin, for prion diseases, 190, 195-196

IS6110 typing method, for *Mycobacterium tuberculosis*, 811

Isoniazid
resistance to, in *Mycobacterium tuberculosis*, 807-808, 824-825, 828, 830, 834
susceptibility to, in *Mycobacterium tuberculosis*, 834-835

Ixodes
in ehrlichiosis, 867, 873-878
in Lyme disease, 867-873

J

JC virus infections, of central nervous system, 858-859

K

Kallmann's syndrome, prenatal diagnosis of, 474

Kaposi's sarcoma, molecular techniques for, 907-909

Karyotypes, prenatal determination of 45,X, 472
46,XX, 472

Karyotyping, electrophoretic, for fungal pathogens, 789

kasA gene mutations, in *Mycobacterium tuberculosis*, resistance in, 808, 825

katG gene mutations, in *Mycobacterium tuberculosis*, resistance in, 824-825, 828, 830-831

Kell antigen, antibodies to, hemolytic disease of the fetus and newborn in, 329

Ki-67 protein, as human papillomavirus surrogate marker, 719-720

Kidney function tests, in preeclampsia, 420-421, 429-430

Klebsiella pneumoniae, molecular epidemiology of, 894

Kleihauer acid elution test, for hemoglobin F, 332-333

Kuru
genetic factors in, 105
neuropathology of, 8, 25
plaques in, 116
scrapie resembling, 139

L

Labor and delivery
for preeclampsia, 418
preterm. *See* Preterm delivery.
rapid HIV testing during, 304

Laminin, in ovarian cancer effusions, 736

Lamivudine, for HIV infection, resistance to, 919

Lecithin/sphingomyelin ratio, for fetal lung maturity
as gold standard, 365-366
centrifugation for, 367-368
in preterm rupture of membranes, 374-375
in test combinations, 372
in twin gestation, 373
racial differences in, 376
technical problems with, 363-364

versus fluorescence polarization, 370-371

Legal issues, in cystic fibrosis prenatal screening, 516-518

Legionella pneumophila, molecular epidemiology of, 893

Leiomyoma, Epstein-Barr virus infections associated with, molecular techniques for, 906-907

Leiomyosarcoma, Epstein-Barr virus infections associated with, molecular techniques for, 906-907

Leptin, in preeclampsia prediction, 426

Leukoencephalopathy, progressive multifocal, 858-859

Lewis antigens, in ovarian cancer effusions, 730-731

Ligase detection reaction, in *Mycobacterium tuberculosis* resistance detection, 833

LightCycler polymerase chain reaction equipment, in *Mycobacterium tuberculosis* resistance detection, 810, 831-832

Liley and Queenan charts, for amniotic fluid bilirubin, 329-332

Limb defects, in chorionic villi sampling, 465-466

Line probe assay, in *Mycobacterium tuberculosis* resistance detection, 808, 830-831

Liquid-based preparations, in gynecologic cytology. *See also* Gynecologic cytology, technology selection for. atypical glandular cells and, 610, 647-648
automation and, 756-759
in atrophy, 672

Listeria monocytogenes, molecular epidemiology of, 888, 894-895

Liver function tests, in preeclampsia, 422

Location guided screening, in cervical cytology, 756, 760

Lopinavir/ritonavir, for HIV infection, resistance to, 920

Lower uterine sampling, cytology of, 641-642

Lung, fetal, maturity of. *See* Fetal lung maturity.

Lung Profile, for fetal lung maturity, 368-369

Lupus anticoagulant, in antiphospholipid syndrome tests for, 269-270 thrombosis and, 275

Lyme disease clinical features of, 869-870 molecular methods for, 870-873 with arthritis, 872 with bloodstream invasion, 871-872 with cutaneous manifestations, 871 with neurologic involvement, 872-873 organism causing, 868-870

Lymph node, biopsy of, in scrapie, 145

Lymphocytosis, polyclonal, Epstein-Barr virus infections associated with, molecular techniques for, 906-907

Lymphoid tissue, prion proteins in, in variant Creutzfeldt-Jakob disease, 100-101

Lymphoma Epstein-Barr virus infections associated with, molecular techniques for, 906-907 herpesvirus-8 infections associated with, molecular techniques for, 907-909

Lymphoreticular system, in scrapie, 188, 200

M

Mad cow disease. *See* Bovine spongiform encephalopathy; Creutzfeldt-Jakob disease, variant.

MAGICChips, in *Mycobacterium tuberculosis* resistance detection, 833

Magnetic resonance imaging in Creutzfeldt-Jakob disease, 112 in variant Creutzfeldt-Jakob disease, 89

Malassezia, molecular methods for, gene amplification, 785

Marker chromosomes, for FISH, 476

Maternal age, Down syndrome screening and, 396-398, 547-548

Matrix metalloproteinases, in ovarian cancer effusions, 735-737, 741

MB/BacT System, for *Mycobacterium tuberculosis* detection, 802

Medroxyprogesterone therapy, cervicovaginal atrophy in, 661, 671-672

Memantine, for prion diseases, 201

Membranes, preterm premature rupture of, fetal lung maturity tests in, 374-375

Meningitis enteroviral. *See* Enteroviral infections, of central nervous system. in Lyme disease, diagnosis of, molecular tools for, 872-873

Menopause atypical squamous cells in, 618-619, 622 cervicovaginal atrophy in, 663, 665-669

Menstrual cycle, cervicovaginal cellular patterns in, 660

Mesothelium, antibodies to, in ovarian cancer effusions, 732

Metalloproteinases, in ovarian cancer effusions, 735-737, 741

Metastasis, from ovarian cancer, effusions and, 735-743

Methicillin, *Staphylococcus aureus* resistant to, molecular epidemiology of, 887, 889-890, 893-894

N-Methyl-D-aspartate antagonists, for prion diseases, 201

MIB-1 antibody, for KI-67 protein recognition, 719

Mice. *See also* specific diseases, murine. prion protein of, structure of, 214

Microarray technology in cancer-associated infections, 905 in human papillomavirus testing, 721-722 in *Mycobacterium tuberculosis* resistance detection, 810, 832-834

Microdeletion syndromes, prenatal diagnosis of, 475

Miller-Dieker syndrome, prenatal diagnosis of, 474

Mink, transmissible encephalopathy of, 139, 234-235

Minocycline, for prion diseases, 196-197

Miscarriage, in antiphospholipid syndrome, 275

Mitogen-activated protein kinase, in ovarian cancer effusions, 744-745

Mixed linker polymerase chain reaction, for *Mycobacterium tuberculosis* typing, 811

Molecular beacons, in *Mycobacterium tuberculosis* resistance detection, 810

Molecular methods

- for antiretroviral resistance in HIV infections, 915-928
- for cancer-associated infections, 903-913
- for ehrlichiosis, 867, 873-878
- for environmental pathogens, 885-901
- for fungal pathogens, 781-799
- for genetic testing. *See also* Cytogenetics.
- in prenatal diagnosis, 473-477, 481-502
- direct mutation analysis in, 482
- DNA sequencing in, 485
- future developments in, 499
- indirect mutation analysis in, 483
- Northern blot in, 484
- of nonclassic inheritance patterns, 490-493
- of single gene disorders, 487-490
- of trinucleotide repeat expansions, 493-496
- polymerase chain reaction in. *See* Polymerase chain reaction.
- preimplantation, 498-499
- Southern blot in, 483-484
- with maternal serum components, 496-498

for hospital pathogens, 885-901

for Lyme disease, 867-873

for *Mycobacterium tuberculosis* resistance, 806-810, 823-841

for nontuberculous mycobacteria, 813-815

for outbreak situations, 885-901

for viral infections, of central nervous system, 843-865

MoM. *See* Multiple of the median.

Monocytes, *Ehrlichia* infection of, 874-875

Mosaicism, prenatal diagnosis of, 472

MS-8209, for prion diseases, 193

Multilocus enzyme typing, of nontuberculous mycobacteria, 814-815

Multilocus sequence typing, for hospital and environmental pathogens, 892-893

Multiple of the median (MoM), in prenatal screening for neural tube defects and Down syndrome, 405-407

- as common currency, 533
- calculation of, 387-389
- definition of, 532
- gestational dating and, 546-547
- grand
- acceptable limits for, 538-540
- action limits on, 537-538
- definition of, 533
- monitoring of, 535-537, 540
- in monitoring report, 549-550
- new values for, 541-543
- periodic recalculation of, 541
- racial factors in, 548

Muscular dystrophy, prenatal diagnosis of, 488-490

Mutation analysis

- for antiretroviral agent resistance, 917-921
- for prenatal diagnosis
- direct, 482
- indirect, 483

MutationScreener Kit, in *Mycobacterium tuberculosis* resistance detection, 808-809

Mycobacteria, nontuberculous

- identification of, 812-814
- typing of, 814-815

Mycobacterial esterases, in *Mycobacterium tuberculosis* susceptibility testing, 806

Mycobacterial interspersed repetitive unit typing, of *Mycobacterium tuberculosis*, 812

Mycobacterium tuberculosis

- laboratory diagnosis of, 801-804
- molecular epidemiology of, 887
- resistance in, 823-841
 - ethambutol, 826
 - isoniazid, 807-808, 824-825, 828, 830, 834
 - mechanisms of, 824-826
 - molecular test methods for, 806-810, 826-834
 - DNA sequencing, 807-808, 827

Mycobacterium (continued)
dot-blot, 831
electrophoresis, 827-830
heteroduplex analysis, 809-810, 829
hybridization, 830-834
invader assay, 830
line probe assay, 830-831
microarray analysis, 810, 832-834
polymerase chain reaction, 827-834
restriction fragment length polymorphism, 828
RNA-RNA mismatch assay, 829-830
single-strand conformation polymorphism, 809, 828
pyrazinamide, 825-826
rifampin, 825, 827-834
streptomycin, 826
susceptibility testing for, 804-806, 834-835
typing of, molecular test methods for, 810-812

Mycolic acid analysis, for nontuberculous mycobacteria detection, 813

N

N-cadherin, in ovarian cancer effusions, 732-733

Nasopharyngeal carcinoma, Epstein-Barr virus infections associated with, molecular techniques for, 906-907

Needle, for amniocentesis, 458-459

Nelfinavir, for HIV infection, resistance to, 920

Neonates
cervicovaginal atrophic pattern in, 659-660
herpes simplex virus infections of, 852-855

Neoplasia, malignant. *See* Cancer.

Nerve growth factor receptors, in ovarian cancer effusions, 739-740

Neural tube defects, open, prenatal screening for, 385-394
alpha-fetoprotein in, 386-393
epidemiologic monitoring of, 531-551
follow-up tests in, 390
laboratory aspects of, 392-393
MoM calculation in, 387-389. *See also* Multiple of the median (MoM). performance evaluation in, 389 protocol for, 390-392

Neurofibrillary tangles, in Gerstmann-Sträussler-Scheinker syndrome, 72-76, 79-81

Neurologic disorders
in familial fatal insomnia, 55-56
in Gerstmann-Sträussler-Scheinker syndrome, 70-82
in hereditary Creutzfeldt-Jakob disease
D178N-129V haplotype, 48
E200K-129 haplotype, 45
E200K-129V haplotype, 48
M232R-129M haplotype, 51
T183A-129M haplotype, 51
V180I-129M haplotype, 51
V210I-129M haplotype, 50
with deletion mutations, 54
with insertion mutations, 53-54
in Lyme disease, diagnosis of, molecular tools for, 872-873
in prion diseases, versus category, 7-10
in variant Creutzfeldt-Jakob disease, 88, 97-100

Neurotrophins, in ovarian cancer effusions, 739-740

Nevirapine, for HIV infection, resistance to, 919

Newborns
cervicovaginal atrophic pattern in, 659-660
herpes simplex virus infections of, 852-855

Nitric oxide, in preeclampsia prediction, 427

Northern blot test, for prenatal diagnosis, 484

Nosocomial infections. *See* Hospital environment.

Nuchal translucency thickness, in Down syndrome, 399, 401-403, 406, 550

Nuclear magnetic resonance
of doppel structure, 215-217
of prion protein structure
normal, 211-215
protease-resistant, 217-219

Nucleic acid sequence analysis
for enteroviruses, 850-851
for fungal pathogens, 792-794

O

Oligohydramnios, fetal lung maturity tests in, 375-376

Oligonucleotide array analysis, for antiretroviral agent resistance, 917

Oligonucleotide ligation, for antiretroviral agent resistance, 917

Omphalocele, alpha-fetoprotein levels in, 389

Oncofetal domain, preterm delivery and, 352-354

Optical density, of amniotic fluid, in hemolytic disease of the fetus and newborn, 329-331

Oral glucose challenge test, in gestational diabetes, 447-448

Ovarian cancer, **727-752**

- effusions in
 - adhesion molecules in, 736, 738-740
 - angiogenic molecules in, 740-741
 - cancer-associated markers in, 735-741
 - clinical significance of, 728-729
 - cytokines in, 740-741
 - diagnostic difficulty in, 729-735
 - flow cytometry of, 732-733
 - immunocytochemistry of, 729-732
 - metastasis-associated markers in, 735-741
 - metastatic sequence and, 741-743
 - nerve growth factor receptors in, 739-740
 - prognostic markers in, 741
 - proteases in, 735-737
 - signal transduction factors in, 743-745
 - telomerase in, 733
 - transcription factors in, 743-745
 - treatment response and, 743-745
- epidemiology of, 727
- spreading patterns of, 727

Oxidative stress, in preeclampsia prediction, 427-428

P

p53 tumor suppressor protein, E6 protein abrogation of, 710

Painting probes, for FISH, 475

Papanicolaou classification, problems with, 585, 587

Papanicolaou smear, significance of, 599-600

Paper-strip line-probes, for antiretroviral agent resistance, 917

PapNet System, 755, 761-762

Parabasal squamous cells, in normal gynecologic cytology, 658

Paracoccidioides brasiliensis, molecular methods for, gene amplification, 784

Paraffin-embedded tissue blot, in prion diseases, 117

Parakeratosis, atypical or pleomorphic, in cervical cytology, 617

Parvovirus B19 infections, prenatal diagnosis of, 296, 299-302, 334-335

Penicillium, molecular methods for, gene amplification, 784

Pentosan sulfate, for prion diseases, 188-189

Peptides, for prion diseases, 191, 197-198

Performance evaluation. *See* Quality control.

Phaeococcomyces, molecular methods for, gene amplification methods, 784

Phagocytophilum ehrlichiosis, 875-877

Phenothiazines, for prion diseases, 191, 199

Phenotypic assays, antiretroviral agent resistance, 921-922

Phosphatidylcholine (lecithin). *See also* Lecithin/sphingomyelin ratio. antibodies to, in antiphospholipid syndrome, 279
in pulmonary surfactant, 366-367, 369-370

Phosphatidylethanolamine, antibodies to, in antiphospholipid syndrome, 271, 276-281

Phosphatidylglycerol antibodies to, in antiphospholipid syndrome, 279
in pulmonary surfactant, 366-369

Phosphatidylinositol, antibodies to, in antiphospholipid syndrome, 279

Phosphatidylserine, antibodies to, in antiphospholipid syndrome, 276, 279-282

Phospholipid(s)
antibodies to. *See* Antiphospholipid syndrome.
binding proteins of, antibodies to, 271-274
in pulmonary surfactant. *See* Fetal lung maturity, pulmonary surfactant in.

Phthalocyanines, for prion diseases, 197

Phytoestrogens, cervicovaginal epithelial effects of, 664

P16INK4a protein, as human papillomavirus surrogate marker, 715-716

Pituitary gland extracts, prion disease transmission in, 130

Placenta
abruption of, preterm delivery in, 348, 351-352
ischemia of, preeclampsia and, 418, 427-428
pathology of, in antiphospholipid syndrome, 276-283
proteins of, in preeclampsia prediction, 424-426

Placenta growth factor, in preeclampsia prediction, 426

Plaques, florid, in variant Creutzfeldt-Jakob disease, 97-100, 116

Plasmid typing, for hospital and environmental pathogens, 886

Plasminogen activator inhibitors, in ovarian cancer effusions, 741

Platelet count, in preeclampsia, 422

pncA gene mutations, in *Mycobacterium tuberculosis*, resistance in, 807, 825-826

Pneumocystis carinii, molecular methods for epidemiologic typing, 793
gene amplification, 783, 786-787
targets of, 782

Pneumonia
aspiration, in chronic wasting disease, 149
in variant Creutzfeldt-Jakob disease, 100

Point mutation assays, for antiretroviral agent resistance, 917

Poliomyelitis, epidemiology of, 844-845

Polyamines, branched, for prion diseases, 191, 198-199

Polyanions, for prion diseases, 188-190, 192

Polyhydramnios, fetal lung maturity tests in, 375-376

Polymerase chain reaction
for anaplasmosis, 868
for antiretroviral agent resistance, 917
for chlrichiosis, 868, 874-878
for enteroviruses, 846-850
for environmental pathogens, 891-892
for Epstein-Barr virus, 906-907
for fungal pathogens, 783-789
conventional, 783-786
multiplex, 786-787
nested, 787-788
real-time, 788-789
for herpes simplex virus, 854-858
for herpesvirus-8, 908-909
for hospital and environmental pathogens, 891-892
for human papillomavirus, 713-714, 909-910
for JC virus, 858-859
for Lyme disease, 868, 870-873
for *Mycobacterium tuberculosis*
detection, 803-804
resistance, 827-834
typing, 811
for prenatal diagnosis
of cytomegalovirus infections, 311
of genetic disorders, 485
of herpes simplex virus infections, 306
of parvovirus infections, 302, 335
of toxoplasmosis, 299
of varicella, 306
for public health outbreaks, 891-892
mixed linker, for *Mycobacterium tuberculosis* typing, 811
real-time
for enteroviruses, 850
for Epstein-Barr virus, 907
reverse-transcriptase
for enteroviruses, 846-850
for Epstein-Barr virus, 906

Polyneuropathy, in Lyme disease, diagnosis of, molecular tools for, 872-873

Polysomnography, in familial fatal insomnia, 56

Porphyrins, for prion diseases, 197

Positron emission tomography, in familial fatal insomnia, 56

Postpartum state, cervicovaginal atrophy in, 661, 671

Prader-Willi syndrome, prenatal diagnosis of, 473-474, 490-493

Preeclampsia, **413-442**
 chronic hypertension superimposed on, 416-417
 definitions of, 415-417
 diagnostic criteria for, 415-417
 epidemiology of, 414
 etiology of, 418-419
 in antiphospholipid syndrome, 274-275, 282-283
 in HELLP syndrome, 417
 laboratory tests for, 420-422
 prediction of, 422-432
 cytokines in, 428-429
 Doppler ultrasound in, 423-424
 endothelial dysfunction in, 426-427
 fat cell DNA testing in, 431
 fibrinolytic activity in, 429
 genetic screening in, 431-432
 insulin resistance in, 430
 oxidative stress in, 427-428
 placental markers in, 424-426
 platelet function in, 428
 renal function in, 429-430
 trophoblast invasion in, 430-431
 prevention of, 419-420
 recurrence risk of, 418
 risk factors for, 414-415
 treatment of, 418

Preeclampsia-eclampsia, definition of, 415-416

Pregnancy
 antiphospholipid syndrome in, **265-293**
 atypical glandular cells in, 634, 646
 atypical squamous cells in, 622
 cervicovaginal cellular patterns in, 660-661
 early, viability of, testing of, **257-264**
 ectopic, testing of, 260-261
 gestational diabetes in, **443-456**
 heterotopic, testing of, 262
 infections in, testing for. *See* Infections, prenatal diagnosis of
 preeclampsia in. *See* Preeclampsia.

Pregnancy-associated plasma protein A in Down syndrome, 399, 401-402, 405-406
 in preeclampsia prediction, 426

Preimplantation genetic testing, 497-498

Premature rupture of membranes, preterm, fetal lung maturity tests in, 374-375

Prenatal interphase FISH, 477

Prenatal testing
 cytogenetics in, **457-480**
 epidemiologic monitoring of, **531-551**
 challenges in, 531
 cutoff levels in, 545
 factors affecting, 544
 gestational dating for, 546-547
 historical aspects of, 533-534
 initial applications of, 534-535
 initial-positive rate monitoring in, 543-544
 marker selection for, 545
 maternal age distribution and, 547-548
 maternal weight distribution and, 548
 multiple of the median in
 action limit definition on, 537-538
 as common currency, 533
 limits on, 538-540
 monitoring of, 535-537, 540-541
 new values for, 541-543
 periodic recalculation of, 541
 racial factors in, 548
 reporting of, 549-550
 terminology of, 532-533

for antiphospholipid syndrome, **265-293**

for autoimmune disease, **265-293**

for cystic fibrosis, 487, **503-530**

for Down syndrome, **395-411, 531-551**

for early pregnancy viability, **257-264**

for fetal lung maturation, **361-383**

for genetic defects, **481-502**

for gestational diabetes, **443-456**

for hematologic disorders, **317-343**

for infectious disease, **295-315**

for neural tube defects, **385-394, 531-551**

for preeclampsia, **413-442**

for preterm delivery risk, **345-360**

Preterm delivery, **345-360**
 biochemical markers of, 349-354
 decidual hemorrhage, 351-352
 fetal fibronectin, 352-354
 genital tract infection, 351
 hypothalamic-pituitary axis hormones, 349-351
 uterine distention, 352

pathogenesis of, 345-349

premature membrane rupture in, fetal lung maturity tests in, 374-375

Primer-extension-based sequence scanning, in *Mycobacterium tuberculosis* resistance detection, 833-834

Prion diseases. *See also specific diseases.* amyloidosis and. *See Amyloidosis.* categories of, 7-10 diagnosis of, 109-127 clinical, 110-114 genetic, 114-115 infectivity assays in, 119-120 neuropathologic methods for, 115-119 protease-resistant prion protein assays in, 120-123 threshold of detection in, 123-124 emerging, 32-33 familial, murine model of, 175-186 construction of, 176 neuropathology of, 177-179 prion proteins in, 179-184 symptoms in, 177 historical review of, 1-2 incubation time of, 26 infectious, phenotypes of, 26-27 list of, 1. *See also specific diseases.* murine models for, 13-18 pathogenesis of, 11-13, 25-26 phenotypes of, 23-32 prion proteins in. *See Prion proteins (PrPs).* protease-resistant prion protein accumulation in, 25 species barriers in, 26 transmission of in blood transfusions, 101-102, 129-137 interspecies and intraspecies, 235-240 treatment of, 32-34, 187-208 acridine derivatives for, 191, 199 anti-prion antibodies for, 191, 199-200 based on prion protein conversion, 240-242 branched polyamines for, 191, 198-199 cholesterol inhibitors for, 201 computational chemistry drugs for, 201 Congo red for, 190, 194-195 dapsone for, 202 iododoxorubicin for, 190, 195-196 lymphoreticular system and, 200 N-methyl-D-aspartate antagonists for, 201 peptides for, 191, 197-198 phenothiazines for, 191, 199 polyanions for, 188-190, 192 polyene antibiotics for, 190, 192-194 sulfated colominic acid for, 201 tetracyclines for, 191, 196-197 tetrapyrroles for, 197

Prion hypothesis, 209, 228-230

Prion proteins (PrPs) amyloidosis and. *See Amyloidosis.* antibodies to, for disease treatment, 199-200 bovine, structure of, 214 characteristics of, 10-11 function of, normal, 217-219 in cerebral amyloid angiopathy, 69 in chronic wasting disease, 150-154 in Creutzfeldt-Jakob disease polymorphisms of, 237 sporadic, 30-32 structures of, 102-103 in familial fatal insomnia, 27-28, 57-58 in Gerstmann-Sträussler-Scheinker syndrome, 29-30, 220-221 animal transmission studies of, 82 characterization of, 66-68 murine model of, 167, 169-171 in hereditary Creutzfeldt-Jakob disease, 27-29 D178N-129V haplotype, 50 E200K-129M haplotype, 48-49 M232R-129M haplotype, 52 T183A-129M haplotype, 51 V180I-129M haplotype, 52 V210I-129M haplotype, 50 with deletion mutations, 54 with insertion mutations, 54 in murine model, 175-186 in scrapie, 142-147 in sheep, structure of, 214 in sporadic Creutzfeldt-Jakob syndrome, 30-32 in sporadic fatal insomnia, 30-31 in variant Creutzfeldt-Jakob disease, 89, 97, 99-104 murine, structure of, 214 normal (cellular) function of, 217-219 in vitro conversion to pathological isoforms, 227-246 cell-free, 232-240 in cell culture, 230-232 process of, 228-230 therapeutic implications of, 240-242 polymorphisms of, 228-230

structure of, 1-4, 10-11, 217-219

polymorphisms in, interspecies and
intraspecies transmissibility and,
235-240

propagation of, 18-23

protease-resistant

- accumulation of, 27-32
- aggregation of, 21-23
- capillary immunoelectrophoresis
for, 120
- conversion from normal proteins
in vitro, 227-246
 - in vivo, 4-5, 11-13, 18-24
- detection of, 109-110
- dissociation-enhanced lanthanide
fluoroimmunoassay for, 120
- immunohistochemistry of,
115-116
- in hereditary Creutzfeldt-Jakob
disease, 44, 48-54
- in tonsillar biopsy, 118-119
- in variant Creutzfeldt-Jakob
disease, 89, 97, 99-104
- in vitro conversion from normal
proteins, 227-246
 - cell-free, 232-240
 - in cell culture, 230-232
 - process of, 228-230
 - therapeutic implications of,
240-242
- in vivo conversion from normal
proteins, 4-5, 11-13, 18-24
- infectivity assays with, 118-119
- neuroanatomic distribution of,
27-32
- paraffin-embedded tissue blot test
for, 117
- properties of, 4-7
- protein-misfolding cyclic amplification
for, 121
- structure of, 10-11
- types of, 44, 46-47
- Western blot test for, 117-118

protein X binding site of, 19-20

strain variation in, 23-32, 234-235

structures of, 10-11, 209-225

- flexible tail, 213
- globular domain, 212-213
- human versus other species, 214
- normal, 217-219
- recombinant, 211-214
- versus doppel, 209-211, 215-217,
219-220

Prion rods (scrapie-associated fibrils), 118

PRNP gene

- discovery of, 2
- mutations of, 2
- detection of, 48-49, 118

in familial fatal insomnia, 27-29,
55-58

in hereditary Creutzfeldt-Jakob
disease, 27-29, 43-54

prion protein amyloidosis. *See*
Amyloidosis, hereditary.

Prnp-Prnd gene complex, in prion disease
animal models, 15-18

Probes, for FISH, 474-475

Progesterone

- cervicovaginal atrophy and, 662-663
- for early pregnancy viability testing,
262-263

Progressive multifocal
leukoencephalopathy, 858-859

Proliferating cell nuclear antigen, as
human papillomavirus surrogate
marker, 720

Prostaglandins, in excess corticotropin-
releasing hormone production, 346

Proteases, in ovarian cancer effusions,
735-737

Protein(s), 14-3-3 type, in Creutzfeldt-Jakob
disease, 111-112

Protein array technology, in human
papillomavirus testing, 721-722

Protein C, as phospholipid-binding
cofactor, 272

Protein-misfolding cyclic amplification, in
prion diseases, 121, 233-234

Proteinuria, in preeclampsia, 414-417,
420-421

Prothrombin, as phospholipid-binding
cofactor, 272-273

PrP^C. *See* Prion proteins (PrPs), normal
(cellular).

PrP^{res}. *See* Prion proteins (PrPs), protease-
resistant.

PrP^{Sc}. *See* Prion proteins (PrPs), protease-
resistant.

Pruritus, in scrapie, 141

Psychiatric disorders, in variant Creutzfeldt-
Jakob disease, 88

Public health environment, molecular
epidemiology in, 885-901

- multilocus sequence typing in, 892-893
- pathogens involved in, 894-895
- plasmid typing methods for, 886
- polymerase chain reaction in, 891-892

Public health environment (continued)
pulsed-field gel electrophoresis in, 887-891
restriction enzymes and probe methods in, 886-887
single-locus sequence typing in, 892-893

Pulmonary surfactant. *See* Fetal lung maturity, pulmonary surfactant in.

Pulsed-gel electrophoresis, for nontuberculous mycobacteria typing, 815

Pyrazinamide, resistance to, in *Mycobacterium tuberculosis*, 807, 810

Q

Quad test, in Down syndrome, 398-399, 401-404, 409

Quality assurance, in cystic fibrosis screening, 525-526

Quality control, in cervical cytology, 693-706
ASCUS/LSIL Triage Study and, 572-573
atypical squamous cells and, 623-626
automated slide selection in, 702-703
AutoPap/Focal Point System, 764
blinded rapid rescreening in, 699-700
directed rescreening in, 695-697
goals of, 693-694
gold standards in, 694
interlaboratory rescreening in, 701-702
masked rescreening in, 697-699
PapNet System, 761-762
seeding of abnormal slides in, 700-701
sensitivity measures in, 694-703
surrogate markers in, 702

Quinacrine, for prion diseases, 34, 199

R

Racial factors
in fetal lung maturity tests, 376
in prenatal testing results, 548

Radiation injury, cervicovaginal atrophy in, 664

Radiculoneuritis, in Lyme disease, diagnosis of, molecular tools for, 872-873

Radioimmunoassay
in Down syndrome screening, 405
in parvovirus infections, 301

Randomly amplified polymorphic DNA (RAPD) assays

for fungal pathogens, 792
for hospital and environmental pathogens, 891-892
for nontuberculous mycobacteria typing, 815

Rep-polymerase chain reaction, for hospital and environmental pathogens, 891-892

Repair cells, atypical, in cervical cytology, 616-617

Replens, cervicovaginal epithelial effects of, 664

Rescreening, in cervical cytology. *See* Quality control, in cervical cytology.

Resistance
to antiretroviral drugs, in HIV infection. *See* Antiretroviral agents, for HIV infection, resistance to.
to antituberculous therapy. *See* *Mycobacterium tuberculosis*, resistance in.

Restriction fragment length polymorphism analysis
for fungal pathogens, 789-790
for hospital and environmental pathogens, 886-887
for *Mycobacterium tuberculosis* resistance, 828
for *Mycobacterium tuberculosis* typing, 811
for nontuberculous mycobacteria identification, 813-814

Retinoblastoma tumor suppression proteins, E7 protein inactivation of, 710

Revised-positive rate, in prenatal screening, definition of, 532

Rh antigen, sensitization to, hemolytic disease of the fetus and newborn in, 319-321, 327-332

Ribotyping, for hospital and environmental pathogens, 886-887

Rifampin
resistance to, in *Mycobacterium tuberculosis*, 825, 827-834
susceptibility to, in *Mycobacterium tuberculosis*, 834-835

Ritonavir, for HIV infection, resistance to, 919

RNA-RNA mismatch assay, in *Mycobacterium tuberculosis* resistance detection, 829-830

Robertsonian translocations, prenatal diagnosis of, 473

rpoB gene mutations, in *Mycobacterium tuberculosis*, resistance in, 808-810, 825-826, 829-834

rspL gene mutations, in *Mycobacterium tuberculosis*, resistance in, 826

S

Sabin-Feldman dye test, in toxoplasmosis, 298-299

Saccharomyces, molecular methods for epidemiologic typing, 791
gene amplification, 785

Saliva, estrogen in, preterm delivery and, 350

Salmonella, molecular epidemiology of, 886, 888, 894-895

Saquinavir, for HIV infection, resistance to, 919

Sarcoma, Kaposi's, molecular techniques for, 907-909

Scanning for intensely fluorescent targets, in prion diseases, 110

Scrapie, 140-147
amyloidosis in, 26-27
clinical features of, 141
diagnosis of, 143-146
epidemiology of, 140-141
genetic factors in, 19-20
incubation time of, 26
murine models of, 165-166
neuropathology of, 8, 25
pathogenesis of, 146-147
pathology of, 141-143
prion proteins of, polymorphisms of, 237-240
treatment of
branched polyamines for, 191, 198-199
Congo red for, 194-195
peptides for, 191, 197-198
polyanions for, 188-189
polyene antibiotics for, 192-193
prion antibodies for, 199-200
tetrapyrroles for, 197

Scrapie-associated fibrils (prion rods), 118

Scytalidium, molecular methods for, epidemiologic typing, 791

Sensitivity, of gynecologic cytology, measures of, 694-703

Septi-Chek system, for *Mycobacterium tuberculosis* detection, 802

Serum Integrated Test, in Down syndrome, 402-403

Sheep
prion protein of, structure of, 214
scrapie of. *See Scrapie*

Shigella, molecular epidemiology of, 888

Sickle cell disease, prenatal diagnosis of, 321-323, 327

SIFT (scanning for intensely fluorescent targets), in prion diseases, 110

Single-locus sequence typing, for hospital and environmental pathogens, 892-893

Single-strand conformation polymorphism, in *Mycobacterium tuberculosis* resistance detection, 809, 828

Skin
biopsy of, for fetal cytogenetic studies, 471
Lyme disease manifestations in, diagnosis of, molecular tools for, 871

Sleep disorders, in fatal insomnia. *See Fatal insomnia*

Smith-Lemli-Optiz syndrome, prenatal screening for, 404-405

Smith-Magenis syndrome, prenatal diagnosis of, 474

Social implications, of cystic fibrosis prenatal screening, 516-518

Southern blot test, for prenatal diagnosis, 483-484

Spacer oligonucleotide typing, of *Mycobacterium tuberculosis*, 811-812

Spina bifida. *See Neural tube defects, open*

Spirochetemia, in Lyme disease, diagnosis of, molecular tools for, 871-872

Spoligotyping, of *Mycobacterium tuberculosis*, 811-812

Spongiform changes
in familial fatal insomnia, 57-58
in Gerstmann-Sträussler-Scheinker syndrome, 70, 73
in hereditary Creutzfeldt-Jakob disease
D178N-I29V haplotype, 49-50

Spongiform changes (continued)
M232R-129M haplotype, 51-52
T183A-129M haplotype, 51
V180I-129M haplotype, 51-52
in variant Creutzfeldt-Jakob disease, 97-100

Spongiform encephalopathy(ies),
transmissible. *See also* Prion diseases.
bovine. *See* Bovine spongiform
encephalopathy.
mink, 139, 234-235

Squamous cells
atypical. *See* Atypical squamous cells.
in cervicovaginal atrophy. *See*
Atrophy, cervicovaginal.
in normal gynecologic cytology, 658

Squamous intraepithelial lesions.
gynecologic. *See also* ASCUS/LSIL
Triage Study.
atrophy and, 668-669
Bethesda System 2001 classification of,
593-594
prevalence of, 644-646
rescreening for, in quality control,
694-702
versus adenocarcinoma in situ,
638-639
versus atypical squamous cells,
606-617

Squamous metaplasia, of cervix, 611-614

Staphylococcus aureus, methicillin-resistant,
molecular epidemiology of, 887,
889-890, 893-894

Stavudine, for HIV infection, resistance to,
919

Steroid sulfatase deficiency, prenatal
diagnosis of, 474

Streptococcus pyogenes, molecular
epidemiology of, 893

Streptomycin, resistance to, in
Mycobacterium tuberculosis, 826

Stress, preterm delivery in, 345-347,
349-351

Stromal cells, endometrial, cytology
of, 642

Subtelomeric probes, for FISH, 474-475

Superfect, for prion diseases, 198-199

SurePath System, for cervical cytology,
757-759

Surfactant, pulmonary. *See* Fetal lung
maturity, pulmonary surfactant in.

Susceptibility testing, of *Mycobacterium*
tuberculosis, molecular test methods
for, 834-835

Syncytiotrophoblast, as antiphospholipid
antibody target, 278, 282

Synovial fluid, molecular analysis of, in
Lyme disease, 872

T

"Taffy pull" morphology, in gynecologic
cytology, 640

TAG-72, in ovarian cancer effusions, 730

Tamoxifen, cervicovaginal epithelial effects
of, 663-664

Tau protein, in Creutzfeldt-Jakob disease,
113-114

Telomerase
as human papillomavirus surrogate
marker, 718-719
in ovarian cancer effusions, 733

Telomeric repeat amplification protocol, in
human papillomavirus testing,
718-719

Temperature-mediated heteroduplex
analysis, in *Mycobacterium*
tuberculosis resistance detection,
809-810

Tenascin, in ovarian cancer effusions, 736

Tenofovir, for HIV infection, resistance to,
919

Tetracyclines, for prion diseases, 191,
196-197

Tetrapyrroles, for prion diseases, 197

Thalassemias, prenatal diagnosis of,
321-327

ThinPrep Pap Test, 757-758

Thrombocytopenia, in preeclampsia, 422

Thrombosis, in antiphospholipid syndrome,
266-269
in placenta, 276-283
systemic, 278

Thromboxanes, in preeclampsia prediction,
428

Tick-borne diseases
ehrlichiosis, 867, 873-878
Lyme disease, 867-873

Tissue culture
of amniotic fluid, 461-462

of chorionic villi, 466-467

Tissue factor, excess of, preterm delivery in, 348

Tissue inhibitors of metalloproteinases, in ovarian cancer effusions, 735-736

Tonsil, biopsy of
in prion diseases, 118-119
in variant Creutzfeldt-Jakob disease, 89

Toxoplasmosis, prenatal diagnosis of, 296-299

Transcription factors, in ovarian cancer effusions, 743-745

Transformation zone, in Bethesda System 2001, 588-589

Transforming growth factor- β , in preeclampsia prediction, 429

Transforming growth factor- β , in ovarian cancer effusions, 740

Transfusions, prion disease transmission in, 129-137
animal studies of, 131
Creutzfeldt-Jakob disease, 133-134
epidemiology of, 131-133
evidence for, 131-133
hazard identification in, 129-131
policy options for, 134-135
variant Creutzfeldt-Jakob disease, 101-102

Transitional cell metaplasia, in cervicovaginal atrophy, 666

Transmissible mink encephalopathy, 139, 234-235

Transmissible spongiform encephalopathies. *See* Prion diseases: specific diseases.

Trichophyton, molecular methods for epidemiologic typing, 792
gene amplification, 786

Trichosporon, molecular methods for, 784

Triglycerides, in preeclampsia prediction, 427-428

Trinucleotide repeat expansions, prenatal diagnosis of, 493-496

Triple test
in Down syndrome screening, 398-399, 401, 409
in preterm delivery prediction, 350-351
in Smith-Lemli-Optiz syndrome, 405

in trisomy 18 screening, 404

Trisomy 18 (Edwards syndrome), prenatal screening for, 404

Trisomy 21. *See* Down syndrome.

Trophoblast
as antiphospholipid antibody target, 278-283
evaluation of, in preeclampsia prediction, 430-431

TruGene kit, for antiretroviral agent resistance, 917-918

Tuberculosis, organism causing. *See* *Mycobacterium tuberculosis*.

Tumor necrosis factor- α
in genital tract infections, preterm delivery and, 347-348
in preeclampsia prediction, 428

Twin pregnancy
alpha-fetoprotein levels in, 389
fetal lung maturity tests in, 373-374

Tyrosine kinase receptors, in ovarian cancer effusions, 739-740

U

Ultrasonography
in amniocentesis, 458-459
in Down syndrome, 399-403, 406
in hemolytic disease of the fetus and newborn, 332
in infection detection
cytomegalovirus, 310
herpes simplex virus, 308
HIV, 303
parvovirus B19, 300-301
toxoplasmosis, 297
varicella, 306
in neural tube defects, 390
in preeclampsia prediction, 423-424

Umbilical cord blood sampling, for cytogenetic studies, 469-471

Uniparental disomy, prenatal diagnosis of, 473

Universal heteroduplex analysis, in *Mycobacterium tuberculosis* resistance detection, 829

Uric acid, excess of, in preeclampsia, 421

Urine
Borrelia nucleic acids in, 873
fetal, cytogenetic studies of, 468-469
protease-resistant prion proteins in, 121-122

Uteroplacental circulation
evaluation of, in preeclampsia
prediction, 423-424
insufficiency of, preterm delivery in,
350-351

Uterus, overdistention of, preterm delivery
in, 348-349, 352

V

Vacuolar degeneration, prion protein
distribution and, 27

Vaginal cytology. *See* Gynecologic
cytology.

Variant Creutzfeldt-Jakob disease. *See*
Creutzfeldt-Jakob disease, variant.

Varicella, prenatal diagnosis of, 296,
305-307

Vascular cell adhesion molecule 1, in
preeclampsia prediction, 430

Vascular endothelial growth factor
in ovarian cancer effusions, 740
in preeclampsia prediction, 430-431

Viral infections, of central nervous system,
molecular diagnosis of, **843-865**
enterovirus, 844-851
herpes simplex virus, 851-858
JC virus, 858-859

ViroSeq kit, for antiretroviral agent
resistance, 917-918

Virtual Phenotype assay, for antiretroviral
agent resistance, 922

Vitamin B₁₂ deficiency, cervicovaginal
epithelial effects of, 664

W

Weight, maternal, prenatal screening and,
548

Western blot test
in HIV infection, 303-304
in parvovirus infections, 301
in prion diseases, 117-118
in variant Creutzfeldt-Jakob disease,
89, 103

Williams syndrome, prenatal diagnosis of,
474

Wolf-Hirschhorn syndrome, prenatal
diagnosis of, 474

X

X chromosomes, markers from, for FISH,
476-477

X-linked disorders, prenatal diagnosis of,
488-490

Y

Zalcitabine, for HIV infection, resistance to,
919

Zidovudine, for HIV infection, resistance
to, 919

